ITRMF (Iterum Therapeutics) EBITDA Margin %: -2,064.36% (As of Sep. 2025)


What is Iterum Therapeutics EBITDA Margin %?

Iterum Therapeutics ITRMF +18.86% EBITDA Margin % is -2,064.36% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Iterum Therapeutics ranks worse than 91.53% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Iterum Therapeutics's EBITDA for the three months ended in Sep. 2025 was $-8.05 Mil. Iterum Therapeutics's Revenue for the three months ended in Sep. 2025 was $0.39 Mil. Therefore, Iterum Therapeutics's EBITDA margin for the quarter that ended in Sep. 2025 was -2,064.36%.

Iterum Therapeutics  (OTCPK:ITRMF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Iterum Therapeutics EBITDA Margin % Related Terms

Iterum Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics EBITDA Margin % Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2,064.36

ITRMF vs ENSC, PPCB, REVB: EBITDA Margin % Comparison

For the Biotechnology subindustry, Iterum Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's EBITDA Margin % falls into.


Iterum Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Iterum Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-21.728/0
= %

Iterum Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-8.051/0.39
=-2,064.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -2,064.36% mean?
Iterum Therapeutics (ITRMF) has a EBITDA Margin % of -2,064.36% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #865 out of 945 companies in the Biotechnology industry, placing it in the top 91.5%.
Is Iterum Therapeutics' EBITDA Margin % too high?
Iterum Therapeutics' current EBITDA Margin % is -2,064.36%. Based on the distribution chart, Iterum Therapeutics ranks #865 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' EBITDA Margin % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #865 out of 945 companies for EBITDA Margin %. This places Iterum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current EBITDA Margin % is -2,064.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current EBITDA Margin % of -2,064.36%. The current EBITDA Margin % is -2,064.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current EBITDA Margin % is -2,064.36% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.